NASDAQ:CPRX Catalyst Pharmaceuticals (CPRX) Stock Price, News & Analysis $17.59 +0.22 (+1.27%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$17.38▼$17.8650-Day Range$14.97▼$17.5652-Week Range$11.55▼$17.99Volume645,492 shsAverage Volume1.30 million shsMarket Capitalization$2.08 billionP/E Ratio32.57Dividend YieldN/APrice Target$27.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Catalyst Pharmaceuticals alerts: Email Address Catalyst Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside58.0% Upside$27.80 Price TargetShort InterestBearish5.26% of Float Sold ShortDividend StrengthN/ASustainability-1.99Upright™ Environmental ScoreNews Sentiment0.63Based on 8 Articles This WeekInsider TradingSelling Shares$1.78 M Sold Last QuarterProj. Earnings Growth20.86%From $1.63 to $1.97 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.70 out of 5 starsMedical Sector66th out of 936 stocksPharmaceutical Preparations Industry21st out of 436 stocks 3.5 Analyst's Opinion Consensus RatingCatalyst Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCatalyst Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Catalyst Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.26% of the float of Catalyst Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCatalyst Pharmaceuticals has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Catalyst Pharmaceuticals has recently increased by 0.94%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCatalyst Pharmaceuticals does not currently pay a dividend.Dividend GrowthCatalyst Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCatalyst Pharmaceuticals has received a 52.55% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Amifampridine" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Catalyst Pharmaceuticals is -1.99. Previous Next 2.0 News and Social Media Coverage News SentimentCatalyst Pharmaceuticals has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Catalyst Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 9 people have searched for CPRX on MarketBeat in the last 30 days. This is a decrease of -31% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Catalyst Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Catalyst Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,777,560.00 in company stock.Percentage Held by Insiders11.00% of the stock of Catalyst Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions79.22% of the stock of Catalyst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Catalyst Pharmaceuticals' insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Catalyst Pharmaceuticals are expected to grow by 20.86% in the coming year, from $1.63 to $1.97 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Catalyst Pharmaceuticals is 32.57, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 142.60.Price to Earnings Ratio vs. SectorThe P/E ratio of Catalyst Pharmaceuticals is 32.57, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 155.18.Price to Book Value per Share RatioCatalyst Pharmaceuticals has a P/B Ratio of 5.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Catalyst Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Catalyst Pharmaceuticals Stock (NASDAQ:CPRX)Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.Read More CPRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CPRX Stock News HeadlinesJuly 24 at 3:11 PM | msn.comCatalyst sells Canadian rights to Duchenne drug to Kye PharmaJuly 24 at 8:05 AM | globenewswire.comCatalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in CanadaJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 23 at 2:15 AM | marketwatch.comCatalyst Pharmaceuticals Inc. stock rises Monday, still underperforms marketJuly 22, 2024 | globenewswire.comCatalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024July 6, 2024 | seekingalpha.comCatalyst Pharmaceuticals: New Products In Proving PhaseMay 30, 2024 | globenewswire.comCatalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®May 28, 2024 | globenewswire.comCatalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 15, 2024 | fool.com2 Incredible Growth Stocks to Buy Hand Over Fist Right NowMay 15, 2024 | fool.com2 Incredible Growth Stocks to Buy Hand Over Fist Right NowMay 10, 2024 | markets.businessinsider.comDecoding 8 Analyst Evaluations For Catalyst PharmaceuticalsMay 8, 2024 | msn.comCPRX Stock Earnings: Catalyst Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024May 8, 2024 | sfgate.comCatalyst: Q1 Earnings SnapshotMay 8, 2024 | msn.comCatalyst Pharmaceuticals Non-GAAP EPS of $0.38 beats by $0.08, revenue of $98.44M misses by $0.33MMay 8, 2024 | globenewswire.comCatalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business UpdateMay 1, 2024 | finance.yahoo.comCatalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024April 25, 2024 | globenewswire.comSanthera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in MaySee More Headlines Receive CPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/26/2024Next Earnings (Confirmed)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CPRX CUSIPN/A CIK1369568 Webwww.catalystpharma.com Phone(305) 420-3200Fax305-529-0933Employees80Year Founded2002Price Target and Rating Average Stock Price Target$27.80 High Stock Price Target$34.00 Low Stock Price Target$23.00 Potential Upside/Downside+58.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)$0.54 Trailing P/E Ratio32.57 Forward P/E Ratio10.79 P/E GrowthN/ANet Income$71.41 million Net Margins15.83% Pretax Margin20.98% Return on Equity25.08% Return on Assets21.26% Debt Debt-to-Equity RatioN/A Current Ratio5.09 Quick Ratio4.83 Sales & Book Value Annual Sales$398.20 million Price / Sales5.22 Cash Flow$2.07 per share Price / Cash Flow8.51 Book Value$3.30 per share Price / Book5.33Miscellaneous Outstanding Shares118,110,000Free Float105,122,000Market Cap$2.08 billion OptionableOptionable Beta0.71 Social Links These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Richard John Daly M.B.A. (Age 63)President, CEO & Director Comp: $68.12kDr. Steven R. Miller Ph.D. (Age 62)Executive VP, COO & Chief Scientific Officer Comp: $884.7kDr. Gary Ingenito M.D. (Age 68)Ph.D., Chief Medical & Regulatory Officer Comp: $811.39kMr. Jeffrey Del Carmen (Age 53)Executive VP & Chief Commercial Officer Comp: $799.82kMr. Michael W. Kalb CPA (Age 53)Executive VP, Treasurer & CFO Ms. Mary ColemanVP & Head of Investor RelationsMr. Brian Elsbernd J.D. (Age 60)Chief Compliance Officer & Chief Legal Officer Comp: $311.42kMr. Pete Curry Sr.Vice President of SalesDr. Stanley Iyadurai M.D.Ph.D., Senior Vice President of Medical Affairs & Drug DiscoveryDr. Preethi Sundaram Ph.D. (Age 48)Chief Strategy Officer Comp: $511.25kMore ExecutivesKey CompetitorsANI PharmaceuticalsNASDAQ:ANIPIDEAYA BiosciencesNASDAQ:IDYAProgenics PharmaceuticalsNASDAQ:PGNXSyros PharmaceuticalsNASDAQ:SYRSDURECTNASDAQ:DRRXView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 16,960 shares on 7/26/2024Ownership: 0.706%Allspring Global Investments Holdings LLCBought 5,007 shares on 7/26/2024Ownership: 0.126%Louisiana State Employees Retirement SystemBought 1,200 shares on 7/24/2024Ownership: 0.048%Summit Global InvestmentsSold 11,333 shares on 7/22/2024Ownership: 0.064%Sumitomo Mitsui Trust Holdings Inc.Sold 11,900 shares on 7/19/2024Ownership: 0.013%View All Insider TransactionsView All Institutional Transactions CPRX Stock Analysis - Frequently Asked Questions How have CPRX shares performed this year? Catalyst Pharmaceuticals' stock was trading at $16.81 at the beginning of 2024. Since then, CPRX shares have increased by 4.6% and is now trading at $17.59. View the best growth stocks for 2024 here. How were Catalyst Pharmaceuticals' earnings last quarter? Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) released its earnings results on Wednesday, May, 8th. The biopharmaceutical company reported $0.31 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.31. The biopharmaceutical company had revenue of $98.51 million for the quarter, compared to the consensus estimate of $97.24 million. Catalyst Pharmaceuticals had a trailing twelve-month return on equity of 25.08% and a net margin of 15.83%. Who are Catalyst Pharmaceuticals' major shareholders? Top institutional investors of Catalyst Pharmaceuticals include Bank of New York Mellon Corp (0.71%), Richard P Slaughter Associates Inc (0.14%), Allspring Global Investments Holdings LLC (0.13%) and Juncture Wealth Strategies LLC (0.08%). Insiders that own company stock include Patrick J Mcenany, Steve Miller, Donald A Denkhaus, Philip H Coelho, Brian Elsbernd, Gary Ingenito, Alicia Grande, Carmen Jeffrey Del, Molly Harper and Preethi Sundaram. View institutional ownership trends. How do I buy shares of Catalyst Pharmaceuticals? Shares of CPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Catalyst Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Catalyst Pharmaceuticals investors own include Novavax (NVAX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Micron Technology (MU) and Verastem (VSTM). This page (NASDAQ:CPRX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Catalyst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Catalyst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.